

VPA10980/026/001

Clavusan 50 mg + 12.5 mg tablets for dogs and cats

Variation	Summary	Date
Vet - B22	VNRA - Vet - B22 - Change to importer, batch control arrangements and quality testing (replacement or addition of a site) for a finished product - B22 Changes to the quality part of the dossier: Change to importer, batch control arrangements and quality testing (replacement or addition of a site) for a finished product	25/03/25
Vet - G.I.3 a)	VRA-S - Vet - G.I.3 a) - a) Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH - G.I.3 a) Safety, Efficacy, Pharmacovigilance changes - Change(s) in the SPC, labelling or package leaflet intended to implement the outcome of a procedure or recommendations from the competent authority or the Agency concerning risk management measures in pharmacovigilance related to veterinary medicinal products - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH	22/07/24
Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	21/06/24
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	21/06/24